# Table of Contents

## Highlights of This Issue  2503

### SPECIAL FEATURES

**CCR Translations**

2505  Minimal Residual Disease in Breast Cancer: In Blood Veritas  
Giulia Siravegna and Alberto Bardelli  
*See related article, p. 2643*

**Molecular Pathways**

2508  Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer  
Alastair M. Thompson

2516  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer  
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

**CCR Focus**

2524  The Language of Pharmacodynamics  
Susan E. Bates

2525  Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine  
William Douglas Figg and David R. Newell

2530  Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology  
Daniel L. Hertz and Howard L. McLeod

2541  Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics  
Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

2553  Circulating Tumor Cells: A Multifunctional Biomarker  
Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

---

## In Vivo Imaging as a Pharmacodynamic Marker  2569

Astrid A.M. van der Veldt and Adriaan A. Lammertsma

## Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations  2578

Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment

## Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer  2508

Alastair M. Thompson

## Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer  2516

Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

## The Language of Pharmacodynamics  2524

Susan E. Bates

## Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine  2525

William Douglas Figg and David R. Newell

## Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology  2530

Daniel L. Hertz and Howard L. McLeod

## Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics  2541

Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

## Circulating Tumor Cells: A Multifunctional Biomarker  2553

Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

---

## FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression  2595

Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

## Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration  2607

Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udai S. Kammula

## miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression  2617

Xuanyu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

## Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2-Negative Feedback Loop Mechanism  2631

Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Moigan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhukowicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniuł, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem

A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga

Lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.
Clinical Cancer Research

20 (10)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/20/10.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.